Jeffrey G. Supko
Massachusetts General Hospital · 295 works · 22,500 citations · h-index 52
Top works
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
- Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
- Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
- Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
- Inhibitors of HIV Nucleocapsid Protein Zinc Fingers as Candidates for the Treatment of AIDS
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
- Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily
- Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study
- Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11
- Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial
- Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia
- Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
- A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
- Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
- A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
- Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
- Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high‐performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry